Anthony Wondka - Soleno Therapeutics Vice President - Research and Development
| SLNO Stock | USD 39.34 0.80 1.99% |
President
Mr. Anthony Wondka is Vice President Research and Development of the Company since 2013.
| Age | 62 |
| Tenure | 11 years |
| Address | 203 Redwood Shores Parkway, Redwood City, CA, United States, 94065 |
| Phone | 650 213 8444 |
| Web | https://soleno.life |
Soleno Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2333) % which means that it has lost $0.2333 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4645) %, meaning that it created substantial loss on money invested by shareholders. Soleno Therapeutics' management efficiency ratios could be used to measure how well Soleno Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.24. At this time, Soleno Therapeutics' Total Assets are very stable compared to the past year. As of the 24th of April 2024, Non Current Assets Total is likely to grow to about 9.9 M, while Non Currrent Assets Other are likely to drop about 141.1 K.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Nick Galli | CytomX Therapeutics | N/A | |
| Jacqueline Papkoff | Assembly Biosciences | 61 | |
| Herman Wijaya | Bolt Biotherapeutics | 75 | |
| Hendra Widjaja | Bolt Biotherapeutics | 65 | |
| Leslie Robbins | CytomX Therapeutics | N/A | |
| Timothy Keutzer | Spero Therapeutics | 56 | |
| Janet LeeSheriff | Instil Bio | N/A | |
| Stephen Garbacz | Spero Therapeutics | 56 | |
| Uri Lopatin | Assembly Biosciences | 45 | |
| Steven Knox | Assembly Biosciences | N/A | |
| David Houck | Assembly Biosciences | 61 | |
| Pinaki Niyogy | Instil Bio | 46 | |
| Cynthia Ladd | CytomX Therapeutics | 61 | |
| Lloyd Rowland | CytomX Therapeutics | 61 | |
| Christopher Keenan | CytomX Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.23 |
Soleno Therapeutics Leadership Team
Elected by the shareholders, the Soleno Therapeutics' board of directors comprises two types of representatives: Soleno Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Soleno. The board's role is to monitor Soleno Therapeutics' management team and ensure that shareholders' interests are well served. Soleno Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Soleno Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kristen MS, Vice Operations | ||
| Steinar Engelsen, Independent Director | ||
| Dr MBA, Senior Development | ||
| Birgitte Volck, Director | ||
| Stuart Collinson, Independent Director | ||
| David OToole, CFO | ||
| Mahendra Shah, Director | ||
| Rajen Dalal, Independent Director | ||
| William Harris, Independent Director | ||
| Meredith MBA, Chief Officer | ||
| Anish MD, CEO and President | ||
| Ernest Mario, Chairman of the Board | ||
| Anish Bhatnagar, President CEO, Director | ||
| Jonathan Wolter, Interim CFO | ||
| James Glasheen, Independent Director | ||
| Anthony Wondka, Vice President - Research and Development | ||
| Gwen Melincoff, Director | ||
| Edgar Engleman, Director | ||
| Stephen Kirnon, Independent Director | ||
| James MacKaness, Chief Officer | ||
| Patricia Hirano, Vice Affairs | ||
| Andrew Sinclair, Director |
Soleno Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Soleno Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 1.13 B | ||||
| Shares Outstanding | 33.41 M | ||||
| Shares Owned By Insiders | 2.06 % | ||||
| Shares Owned By Institutions | 97.68 % | ||||
| Number Of Shares Shorted | 2.76 M | ||||
| Price To Earning | (3.71) X | ||||
| Price To Book | 7.65 X | ||||
| EBITDA | (36.71 M) |
Currently Active Assets on Macroaxis
When determining whether Soleno Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Soleno Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Soleno Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Soleno Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Soleno Stock analysis
When running Soleno Therapeutics' price analysis, check to measure Soleno Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Soleno Therapeutics is operating at the current time. Most of Soleno Therapeutics' value examination focuses on studying past and present price action to predict the probability of Soleno Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Soleno Therapeutics' price. Additionally, you may evaluate how the addition of Soleno Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stocks Directory Find actively traded stocks across global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Soleno Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.36) | Return On Assets (0.23) | Return On Equity (0.46) |
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.